Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5280188
Max Phase: Preclinical
Molecular Formula: C53H61FN10O8S
Molecular Weight: 1017.20
Associated Items:
ID: ALA5280188
Max Phase: Preclinical
Molecular Formula: C53H61FN10O8S
Molecular Weight: 1017.20
Associated Items:
Canonical SMILES: Cc1ncsc1-c1ccc([C@H](C)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NCCOCCOCCn2cc(CNc3cccc(Cc4c(C)c5ccc(Oc6ncccn6)cc5oc4=O)c3F)nn2)C(C)(C)C)cc1
Standard InChI: InChI=1S/C53H61FN10O8S/c1-32-41-16-15-40(71-52-56-17-8-18-57-52)27-45(41)72-51(68)42(32)25-37-9-7-10-43(46(37)54)58-28-38-29-63(62-61-38)20-22-70-24-23-69-21-19-55-48(53(4,5)6)50(67)64-30-39(65)26-44(64)49(66)60-33(2)35-11-13-36(14-12-35)47-34(3)59-31-73-47/h7-18,27,29,31,33,39,44,48,55,58,65H,19-26,28,30H2,1-6H3,(H,60,66)/t33-,39+,44-,48+/m0/s1
Standard InChI Key: DHACDBHLGBCXSX-WQWWALRQSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 1017.20 | Molecular Weight (Monoisotopic): 1016.4379 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Wang C, Wang H, Zheng C, Li B, Liu Z, Zhang L, Yuan L, Xu P.. (2023) Discovery of Coumarin-Based MEK1/2 PROTAC Effective in Human Cancer Cells., 14 (1.0): [PMID:36655129] [10.1021/acsmedchemlett.2c00446] |
Source(1):